Cypress Growth Fund III’s Teladoc Health TDOC Stock Holding History

Cypress Growth Fund III’s Portfolio TDOC Stock Details TDOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,000	Closed	-$1.82M	–	34
2021 Q1	$1.82M	Buy	10,000 +5,000	+100%	+$1.16M	1.57%	29
2020 Q4	$1M	Buy	+5,000	New	+$1.02M	0.86%	32

Other funds holding TDOC

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

GCGM

General Catalyst Group Management Cambridge, Massachusetts $189M AUM 10.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cypress Growth Fund III's TDOC Position: Q2 2021 in Review

Cypress Growth Fund III sold out of Teladoc Health (TDOC) in Q2 2021, closing a stake of 10,000 shares — an estimated $1.82M sold.

Cypress Growth Fund III first reported a position in TDOC in Q4 2020 and held it in 2 quarters. The position peaked at $1.82M in Q1 2021. 829 funds tracked by Wall St. Rank hold TDOC as of Q2 2021.

Cypress Growth Fund III reported no remaining Teladoc Health position as of Q2 2021 after selling out during the quarter.
Cypress Growth Fund III sold 10,000 Teladoc Health shares in Q2 2021, an estimated $1.82M.
Cypress Growth Fund III first reported a position in Teladoc Health in Q4 2020 and held it in 2 quarters.
Cypress Growth Fund III's Teladoc Health position peaked at $1.82M in Q1 2021.
829 funds tracked by Wall St. Rank held Teladoc Health as of Q2 2021.

Based on Cypress Growth Fund III's 13F filing for Q2 2021, filed 13 Jul 2021.